LRI Investments’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$460K Hold
2,933
0.04% 196
2026
Q1
$448K Buy
2,933
+155
+6% +$23.8K 0.04% 190
2025
Q4
$383K Sell
2,778
-116
-4% -$15.2K 0.03% 200
2025
Q3
$371K Buy
2,894
+116
+4% +$14.2K 0.03% 209
2025
Q2
$336K Buy
2,778
+44
+2% +$4.96K 0.03% 218
2025
Q1
$305K Hold
2,734
0.03% 212
2024
Q4
$266K Sell
2,734
-2,000
-42% -$213K 0.03% 219
2024
Q3
$490K Buy
4,734
+2,566
+118% +$291K 0.05% 152
2024
Q2
$231K Buy
2,168
+2,000
+1,190% +$201K 0.03% 224
2024
Q1
$16.3K Buy
+168
New +$17.2K ﹤0.01% 409

Other funds holding NVS

LRI Investments's NVS Position: Q2 2026 in Review

LRI Investments held its Novartis (NVS) position steady in Q2 2026 at 2,933 shares worth $460K. The position accounts for 0.04% of the portfolio, ranked #196.

LRI Investments first reported a position in NVS in Q1 2024 and has held it in 10 quarters since. The position peaked at $490K in Q3 2024. 717 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • LRI Investments held 2,933 shares of Novartis worth $460K as of Q2 2026.
  • LRI Investments left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.04% of LRI Investments's portfolio in Q2 2026, its #196 holding.
  • LRI Investments first reported a position in Novartis in Q1 2024 and has held it in 10 quarters since.
  • LRI Investments's Novartis position peaked at $490K in Q3 2024.
  • 717 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.